Phase 3
N=512
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Renal Cell Carcinoma
Bottom Line
View on ClinicalTrials.gov: NCT00474786 ↗Enrolled (actual)
512
Serious AEs
38.1%
Results posted
Mar 2013
Primary outcome: Primary: Progression-Free Survival (PFS) — 4.28; 3.91 months — p=0.1933
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Sorafenib (Drug); temsirolimus (Torisel) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Jan 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-Free Survival (PFS) |
4.28; 3.91 | 0.1933 |
| SECONDARY Progression Free Survival (PFS) by Investigator Assessment |
5.43; 4.14 | 0.1888 |
| SECONDARY Percentage of Participants With Tumor Response |
7.7; 7.9 | — |
| SECONDARY Overall Survival (OS) |
12.27; 16.64 | 0.0144 sig |
| SECONDARY Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment |
31.2; 36.7; 20.9; 20.1; 12.3; 11.2 | — |
| SECONDARY Duration of Response (DR) |
8.26; 6.96 | — |
Summary
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID). These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months. Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy status) with well-documented Radiological PD by RECIST criteria or clinical PD as judged by the investigator while receiving first-line sunitinib therapy. Subjects must have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).
- At time of randomization, at least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery.
- At time of randomization, there must be at least 1 measurable lesion per RECIST. Lesions that have been previously irradiated or embolized cannot be selected as target lesions.
- More criteria apply
Exclusion Criteria
- Metastatic CNS from RCC.
- Subjects who discontinued Sutent therapy due specifically to intolerance.
- Prior systemic therapy for mRCC other than sunitinib.
- Active ketonuria, secondary to poorly controlled diabetes mellitus
- More criteria apply
Data sourced from ClinicalTrials.gov (NCT00474786). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.